Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Authors
Keywords
-
Journal
Pharmaceutics
Volume 13, Issue 5, Pages 653
Publisher
MDPI AG
Online
2021-05-06
DOI
10.3390/pharmaceutics13050653
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
- (2020) Louis Buscail et al. Nature Reviews Gastroenterology & Hepatology
- CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.
- (2020) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
- (2020) Zi-Nan Li et al. Gastroenterology Report
- 1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
- (2020) M. Reck et al. ANNALS OF ONCOLOGY
- KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
- (2020) P.A. Jänne et al. EUROPEAN JOURNAL OF CANCER
- MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
- (2020) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the untargetable KRAS in cancer therapy
- (2019) Pingyu Liu et al. Acta Pharmaceutica Sinica B
- A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
- (2019) Thorvardur R. Halfdanarson et al. ONCOLOGIST
- Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
- (2019) Badi El Osta et al. Journal of Thoracic Oncology
- Impact of gene-specific germline pathogenic variants on presentation of endometrial cancer in Lynch syndrome
- (2019) Giorgio Bogani et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- The Role of KRAS in Endometrial Cancer: A Mini-Review
- (2019) MICHAIL SIDERIS et al. ANTICANCER RESEARCH
- Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review
- (2019) Ritu R. Singh et al. CANCER TREATMENT REVIEWS
- K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
- (2019) Matthias Scheffler et al. Journal of Thoracic Oncology
- Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer
- (2019) Els Van Nieuwenhuysen et al. NEOPLASIA
- LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042
- (2019) R S Herbst et al. ANNALS OF ONCOLOGY
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- Low-grade serous ovarian carcinoma: an evolution toward targeted therapy
- (2019) Ioannis A Voutsadakis INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies
- (2019) Ioanna Giopanou et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- TP53,STK11andEGFRMutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma
- (2018) Jerome Biton et al. CLINICAL CANCER RESEARCH
- Recent Development of Small Molecule Glutaminase Inhibitors
- (2018) Minsoo Song et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
- (2018) Eric Van Cutsem et al. INTERNATIONAL JOURNAL OF CANCER
- The dTAG system for immediate and target-specific protein degradation
- (2018) Behnam Nabet et al. Nature Chemical Biology
- A treatment strategy for KRAS-driven tumors
- (2018) Trang T. Mai et al. NATURE MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells
- (2018) Wookjae Lee et al. Scientific Reports
- Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
- (2018) Francesco Passiglia et al. BRITISH JOURNAL OF CANCER
- Molecular approaches for classifying endometrial carcinoma
- (2017) Josep M Piulats et al. GYNECOLOGIC ONCOLOGY
- Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition
- (2017) Kari L. Ring et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
- (2017) Sushrut Kamerkar et al. NATURE
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
- (2017) Jung Han Kim et al. Oncotarget
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
- (2016) Barbara Bournet et al. EUROPEAN JOURNAL OF CANCER
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- (2016) Ying-Nan P. Chen et al. NATURE
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
- (2016) Joshua D Campbell et al. NATURE GENETICS
- KRAS-related proteins in pancreatic cancer
- (2016) Karen M. Mann et al. PHARMACOLOGY & THERAPEUTICS
- Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
- (2016) Jean-Luc Van Laethem et al. Targeted Oncology
- KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review
- (2016) Bum Jun Kim et al. Oncotarget
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- KRAS as a Therapeutic Target
- (2015) F. McCormick CLINICAL CANCER RESEARCH
- A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
- (2015) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer
- (2015) Johan F. Vansteenkiste et al. Journal of Thoracic Oncology
- Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer
- (2015) M. Porru et al. MOLECULAR CANCER THERAPEUTICS
- RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
- (2015) Talia Golan et al. Oncotarget
- Critical role of NF-κB in pancreatic cancer
- (2015) Lakshmi Prabhu et al. Oncotarget
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
- (2014) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas
- (2014) Charlie Gourley et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs
- (2014) C. V. Pecot et al. MOLECULAR CANCER THERAPEUTICS
- An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition
- (2014) Laetitia Seguin et al. NATURE CELL BIOLOGY
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR
- (2014) P. J. Belmont et al. Science Signaling
- Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9
- (2014) Jifu E et al. TUMOR BIOLOGY
- Development of siRNA Payloads to Target KRAS-Mutant Cancer
- (2014) T. L. Yuan et al. Cancer Discovery
- Roles for KRAS in Pancreatic Tumor Development and Progression
- (2013) Marina Pasca di Magliano et al. GASTROENTEROLOGY
- ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells
- (2013) Chunning Zheng et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
- (2013) Cosimo Commisso et al. NATURE
- Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
- (2013) Gunther Zimmermann et al. NATURE
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
- (2012) John Farley et al. LANCET ONCOLOGY
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Genetic and Epigenetic Alterations in Pancreatic Carcinogenesis
- (2011) Yannick Delpu et al. CURRENT GENOMICS
- A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
- (2010) Jaafar Bennouna et al. INVESTIGATIONAL NEW DRUGS
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation
- (2008) George Fountzilas et al. CANCER INVESTIGATION
- Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
- (2008) G. J. Riely et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started